#ASCO21: AstraZeneca's Lynparza earns win in early breast cancer patients, cracking open post-surgery potential
Drugmakers’ race to take targeted cancer therapies into early-line patients — before the disease ever spreads or can’t be removed surgically — has reached a fever pitch …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
